Definitive Healthcare (NASDAQ:DH) Issues Q3 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its third quarter 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.070-0.080 for the period, compared to the consensus EPS estimate of 0.090. The company issued revenue guidance of $61.0 million-$62.5 million, compared to the consensus revenue estimate of $63.7 million.

Definitive Healthcare Price Performance

Shares of NASDAQ DH traded up $0.07 during mid-day trading on Friday, hitting $3.90. 81,384 shares of the stock traded hands, compared to its average volume of 821,425. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.30 and a quick ratio of 2.30. Definitive Healthcare has a twelve month low of $3.19 and a twelve month high of $11.01. The company has a market cap of $459.95 million, a PE ratio of -2.19, a price-to-earnings-growth ratio of 4.58 and a beta of 1.30. The firm has a 50 day simple moving average of $5.34 and a two-hundred day simple moving average of $6.94.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Monday, August 5th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. The firm had revenue of $63.70 million for the quarter, compared to the consensus estimate of $63.19 million. Definitive Healthcare had a positive return on equity of 0.51% and a negative net margin of 78.16%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.08 EPS. As a group, equities research analysts forecast that Definitive Healthcare will post 0.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on DH shares. Barclays lowered their price objective on Definitive Healthcare from $6.00 to $4.00 and set an equal weight rating for the company in a research report on Wednesday. Canaccord Genuity Group decreased their target price on Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a research report on Wednesday, May 8th. Needham & Company LLC reaffirmed a hold rating on shares of Definitive Healthcare in a research report on Tuesday. Deutsche Bank Aktiengesellschaft decreased their target price on Definitive Healthcare from $10.00 to $7.00 and set a hold rating for the company in a research report on Thursday, May 9th. Finally, William Blair reaffirmed an outperform rating on shares of Definitive Healthcare in a research report on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $7.75.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.